Dianthus therapeutics announces oral presentation for dnth103 at the 2024 american academy of neurology (aan) annual meeting

New york and waltham, mass., april 11, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for dnth103 at the american academy of neurology (aan) annual meeting, taking place april 13-18, 2024 in denver, colorado and virtually.
DNTH Ratings Summary
DNTH Quant Ranking